activeriskyoutube

The Longevity Singularity: Age Reversal in 2026 & David’s Updated Protocols | David Sinclair EP #250

David Sinclair discusses an accelerated longevity narrative and updated personal protocols in a podcast episode framing a possible age‑reversal ‘‘singularity’’ emerging by 2026. The thesis: if true rejuvenation therapies materialize, they pose long‑term disruption risk to chronic disease franchises (ophthalmology, neurodegeneration). The evidence in these sources is largely thematic and speculative rather than near‑term actionable.

Confidence
16 / 100
Assets
3
Authors
1
Outcome
open

Linked assets

REGN (Regeneron), RHHBY (Roche), BIIB (Biogen). These companies have meaningful exposure to ophthalmology and neurodegenerative disease markets that could be affected over the long run by validated rejuvenation therapies. Any practical impact would be highly uncertain and distant relative to current clinical and commercial timelines.

REGNriskopen
Confidence: 16 / 100Start: $708.00Latest: $708.00Return: 0.00%

Regeneron has a major ophthalmology franchise; durable ocular rejuvenation could theoretically compete with chronic retinal treatments over the very long term, though no near-term impact is implied.

RHHBYriskopen
Confidence: 14 / 100Start: $50.45Latest: $50.45Return: 0.00%

Roche has ophthalmology and neurodegeneration exposure; broad rejuvenation therapies could one day alter these markets, but the connection is speculative.

BIIBriskopen
Confidence: 12 / 100Start: $186.97Latest: $186.97Return: 0.00%

Biogen is exposed to neurodegenerative disease markets that could be reshaped by true brain-age reversal, but this is far beyond the current evidence base.

Source proof

Source proof: Strong source proof | 3 directional assets | 1 supporting author | headline-like title review

Primary inputs are podcast episodes and conversational transcripts that outline a 10+ year technology and biomedical narrative. Content is thematic, often fragmented, and contains few verifiable catalysts, filings, dates, or concrete clinical data. Use these sources to frame medium‑to‑long horizon positioning, not as immediate trade signals.

Brian Armstrong on Bitcoin, Anthropic Drops Fable 5 & Mythos 5, NewLimit's $435M Age-Reversal | 264
Peter H. Diamandis · Jun 11, 2026, 11:33 AM EDT

Brian Armstrong on Bitcoin, Anthropic Drops Fable 5 & Mythos 5, NewLimit's $435M Age-Reversal | 264 This episode is a dense Moonshots roundtable on Bitcoin, agentic payments, government stakes in AI companies, the OpenAI IPO, SpaceX’s compute expansion, Apple’s Siri reboot, and longevity biotech. Get access to metatrends 10+ years before anyone else - https://qr.diamandis.com/metatrends Peter H. Diamandis, MD, is the Founder of XPRIZE, Singularity University, ZeroG, and A360 Brian Armstrong is the Co-founder and CEO of Coinbase. Salim Ismail is the founder of Open ExO, a GP at Exponential Venture Capital/The Organizational Singularity Fund and a sought after global speaker and thought leader. Apply for Salim’s Pilot Program: https://openexo.com/organizational-singularity-pilot?podcast=23.5.26 Dave Blundin is the founder & GP of Link Ventures Dr. Alexander Wissner-Gross is a computer scientist and founder of Reified Chapters 00:00 - Intro 03:50 - BTC’s Future Outlook 15:00 - What is the Quantum BTC Risk? 20:50 - Coinbase Says the Agent Economy Has Arrived 31:30 - US government Exploring Ownership Stakes in AI Companies 45:00 - Sam Altman Meets With Sen. Bernie Sanders on 50% AI Equi

View source
Emerging Situation: Anthropic's Global Pause, Recursive Self-Improvement, and AI Personhood Arrives
Peter H. Diamandis · Jun 8, 2026, 2:30 PM EDT

Low-coherence transcript-style text referencing: (1) a purported “global pause” by Anthropic, (2) recursive self-improvement / AI personhood themes, (3) Elon Musk/xAI deal expansion (unspecified counterpart), and (4) Argentina positioning as a global hub (compute/AI) amid opposition/regulatory capture. Most statements are non-specific, lack verifiable details (who/what/when), and provide limited direct trading catalysts.

View source
Anthropic Files $965B IPO, Trump Signs AI Executive Order, and ChatGPT Crosses 1B Users | EP #262
Peter H. Diamandis · Jun 6, 2026, 11:00 AM EDT

Anthropic Files $965B IPO, Trump Signs AI Executive Order, and ChatGPT Crosses 1B Users | EP #262 In this episode, the mates discuss the Anthropic IPO filing, Trump signing the AI Executive Order, and more. Get access to metatrends 10+ years before anyone else - https://qr.diamandis.com/metatrends Peter H. Diamandis, MD, is the Founder of XPRIZE, Singularity University, ZeroG, and A360 Emad Mostaque is the founder of Intelligent Internet ( https://www.ii.inc ) Dave Blundin is the founder & GP of Link Ventures Dr. Alexander Wissner-Gross is a computer scientist and founder of Reified – My companies: Apply to Dave's and my new fund: https://qr.diamandis.com/linkventureslanding Go to Blitzy to book a free demo and start building today: https://qr.diamandis.com/blitzy Your body is incredibly good at hiding disease. Schedule a call with Fountain Life to add healthy decades to your life, and to learn more about their Memberships: https://www.fountainlife.com/peter _ Chapters 00:00 - Anthropic's IPO and AI Market Dynamics 02:56 - US Government's AI Executive Order and National Security 05:39 - OpenAI's Rapid Growth and User Adoption 11:17 - The Future of Robotics and AI Infrastructure 14:

View source
Ray Kurzweil on Why We’re Living in the Singularity | EP #261
Peter H. Diamandis · Jun 3, 2026, 4:05 PM EDT

Ray Kurzweil on Why We’re Living in the Singularity | EP #261

View source
Opus 4.8 Beats GPT 5.5, the $220B OpenAI Foundation, and Hassabis’s 2029 AGI Prediction | EP #260
Peter H. Diamandis · Jun 1, 2026, 5:15 PM EDT

Podcast discussion spans: Anthropic’s Opus 4.8 vs “GPT 5.5” narrative, OpenAI “foundation”/philanthropy, Hassabis AGI-by-2029 view, Amazon AI shopping, renewables surpassing legacy energy, AI/robots accelerating, cancer detection innovation, and social/political backlash (anti-tech extremism, UBI, workforce initiatives). Content is thematic (10+ year tech narrative) with limited concrete catalysts/tickers; best used to frame medium-term positioning in AI infrastructure, hyperscalers, robotics automation, and renewables, while noting regulatory/backlash risk to big tech.

View source
Pope Leo on AI, Sam Altman’s Job Loss Predictions, and the Truth About Tech Layoffs in 2026| EP #259
Peter H. Diamandis · May 30, 2026, 11:00 AM EDT

Podcast-style, low-coherence transcript touching on (1) a major religious institution (the Vatican/Pope Leo) taking a position related to AI philosophy/AI personhood, framed as potentially aligning with EU-style caution; (2) references to frontier labs (Anthropic, xAI) and upcoming model iterations (e.g., “GPT 5.5”); and (3) a claim that Anthropic’s revenue is growing/has shifted toward a “real revenue engine,” plus a provocative/unclear claim that something “could surpass Alphabet’s total revenue,” with an isolated “$9 billion in revenu…” fragment. The entry contains some narrative signals (regulatory/ethical headwinds; frontier model progress; commercialization traction) but few verifiable, trade-ready facts.

View source
The New Era of Jobs: Organizational Singularity | EP #258
Peter H. Diamandis · May 26, 2026, 11:00 AM EDT

Podcast-style discussion (fragmented transcript) about an "organizational singularity" driven by increasingly capable AI agents (AGI/ASI framing). Core idea: companies will restructure around a mission/protocol/architecture ("MTP") with agentic loops (similar to OODA/UDA loops), where agents operate via APIs, potentially changing how work is organized and how enterprise systems (ERP) are implemented/used. It references legacy enterprise stacks (Oracle Financials, SAP) and suggests SaaS/ERP vendors may be "freaked out" if agentic layers/protocols commoditize or bypass traditional ERP workflows.

View source
SpaceX’ $75B+ Historic IPO, GPT5.5 Outperforms Polymarket, AI Solves 80yr old math problem | EP #257
Peter H. Diamandis · May 23, 2026, 3:20 PM EDT

The source contains only a headline with no supporting details, timing, or specifics (no confirmed filing, terms, or catalyst dates). Actionability is therefore low; at best it suggests broad themes (space/launch, AI model performance) that could map to public proxies.

View source

Supporting authors

1 author/source contributed to this play. The material is presented in podcast/transcript format and reflects opinionated, thematic discussion rather than peer‑reviewed clinical evidence or regulatory filings.

Unlock full thesis monitoring

Monitor clinical trial readouts, regulatory milestones, and peer‑reviewed evidence for rejuvenation therapies; reassess exposure in ophthalmology and neurodegeneration franchises if credible, reproducible human age‑reversal data emerges. Follow this play for updates and episode links.